NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

美國的牙科用替代骨移植片市場分析 - 新型冠狀病毒感染疾病 (COVID-19)的影響 (2021年∼2027年):MedSuite (含牙科用替代骨移植片,牙科用生長因子,牙科用阻隔薄膜設備)

U.S. Dental Bone Graft Substitutes Market Analysis - COVID19 - 2021-2027 - MedSuite - Includes: Dental Bone Graft Substitutes, Dental Growth Factor & Dental Barrier Membrane Devices

出版商 iData Research Inc. 商品編碼 1000913
出版日期 內容資訊 英文 211 Pages
商品交期: 最快1-2個工作天內
價格
美國的牙科用替代骨移植片市場分析 - 新型冠狀病毒感染疾病 (COVID-19)的影響 (2021年∼2027年):MedSuite (含牙科用替代骨移植片,牙科用生長因子,牙科用阻隔薄膜設備) U.S. Dental Bone Graft Substitutes Market Analysis - COVID19 - 2021-2027 - MedSuite - Includes: Dental Bone Graft Substitutes, Dental Growth Factor & Dental Barrier Membrane Devices
出版日期: 2020年12月23日內容資訊: 英文 211 Pages
簡介

本報告提供美國的牙科用替代骨移植片的市場相關分析,近來的市場主要趨勢及其背景情況,整體市場規模趨勢預測,各市場區隔詳細趨勢,主要企業 (共41家公司)的市場規模、銷售量、平均銷售價格 (ASP)、市場佔有率,新型冠狀病毒感染疾病 (COVID-19) 感染擴大的影響等調查。

分析對象市場:

牙科用替代骨移植片市場 - MedCore

牙科用生長因子市場 - MedCore

牙科用阻隔薄膜市場 - MedCore

美國的牙科骨移植片市場洞察:

美國的牙科用骨移植替代品的市場規模,2020年達到了3億1600萬美元以上。但,與2019年比較為-21%。僅管有新型冠狀病毒感染疾病 (COVID-19) ,美國市場預計持續擴大趨勢,2027年達到5億4000萬美元以上。

牙科骨移植片替代品 (BDGS) 以及其他生物材料的市場上的趨勢之一,是大量的植入物購買伴隨的DBGS材料的套組銷售 (大幅度折扣或無償提供) 。美國 (可植入治療) 的牙周病專門醫生和口腔外科醫生數超過一般開業醫生,這些專門醫生由於有大量購買的趨勢,這個趨勢今後預計將持續。另一方面,由於免費的DBGS產品,整體市場規模降低,也妨礙市場成長。

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: iDATA_USDBGS21_MS

Throughout this medical market research, iData Research analyzed 41 dental bone graft substitutes device companies in the US and utilized their comprehensive methodology to understand the Market Sizes, Unit Sales, ASPs, Company Market Shares, and to create accurate forecasts.

While this MedSuite report contains all of US Dental Bone Graft Substitutes Market analysis, each of the market segments is also available for purchase as a stand-alone report, MedCore.

Markets Covered:

  • Dental Bone Graft Substitute Market - MedCore
  • Dental Growth Factor Market - MedCore
  • Dental Barrier Membrane Market - MedCore

US Dental Bone Graft Substitutes Market Insights

In 2020, the US dental bone graft substitutes market size was valued at over $316 million, which declined at -21% when compared to 2019. In spite of COVID19, the US market size is expected to increase over the forecast period to exceed $540 million in 2027.

One trend within the dental bone graft substitute and other biomaterials markets is the bundling of DBGS materials with large-volume implant purchases, rendering the products extremely discounted or even complimentary. Because periodontists and oral surgeons outnumber general practitioners in terms of the number of dentists placing implants in the United States, and because these specialists tend to buy in bulk, this trend is expected to persist in the future. Free DBGS products limit the market by dragging down the overall market value.

Geistlich was the leader of the dental biomaterials market in the U.S. in 2020. Its prominence in the overall market is fueled primarily by the company's continued leadership in the xenograft DBGS segment. Geistlich's Bio-Oss® bovine xenograft product line is recognized as the gold standard for xenograft products and correspondingly represented about two-thirds of the xenograft segment.